{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:39:17Z","timestamp":1792841957373,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.brachy.2026.08.004","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:57:12Z","timestamp":1790913432000},"page":"1016-1031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypofractionated 44 Gy in 20 fractions versus conventional chemoradiation in cervical cancer: 2-year results of the randomized HYPOCx-iRex trial with an exploratory pooled analysis of a single-institute EMBRACE-II cohort"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-8861","authenticated-orcid":false,"given":"Tissana","family":"Prasartseree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pittaya","family":"Dankulchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0334-2551","authenticated-orcid":false,"given":"Wiwatchai","family":"Sittiwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phattarapol","family":"Laolugsanalerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5481-3734","authenticated-orcid":false,"given":"Sirapob","family":"Seksunwiriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1779-4801","authenticated-orcid":false,"given":"Soponvit","family":"Wattanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tewpaithong","family":"Rodwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peerakarn","family":"Charoenwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2298-7125","authenticated-orcid":false,"given":"Wasawat","family":"Jirasuviboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonpawit","family":"Suriyanusorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akrapol","family":"Suppasedtanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7182-0733","authenticated-orcid":false,"given":"Chayanis","family":"Kositamongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pochamana","family":"Phisalprapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann H.","family":"Klopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2026.08.004_bib0001","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/ijgc-2023-004429","article-title":"ESGO\/ESTRO\/ESP Guidelines for the management of patients with cervical cancer \u2013 Update 2023","volume":"33","author":"Cibula","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.brachy.2026.08.004_bib0002","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","article-title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study","volume":"22","author":"P\u00f6tter","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.brachy.2026.08.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2024.08.003","article-title":"Clinical outcome comparison between CT-guided versus all MRI-guided scenarios in brachytherapy for cervical cancer: a single-institute experience","author":"Dankulchai","year":"2024","journal-title":"Clin Oncol"},{"key":"10.1016\/j.brachy.2026.08.004_bib0004","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.radonc.2021.01.003","article-title":"Hypofractionated radiotherapy in the real-world setting: an international ESTRO-GIRO survey","volume":"157","author":"Rodin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2026.08.004_bib0005","doi-asserted-by":"crossref","first-page":"e695","DOI":"10.1016\/j.ijrobp.2024.07.1529","article-title":"Hypofractionated radiotherapy in treatment of cervical cancer: a systematic review","volume":"120","author":"Kibudde","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2026.08.004_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2025.103907","article-title":"Early results of hypofractionated chemoradiation in cervical cancer with 44 Gy\/20F VS 45 Gy\/25F: a phase II, open-label, randomized controlled trial (HYPOCx-iRex trial)","author":"Dankulchai","year":"2025","journal-title":"Clin Oncol"},{"key":"10.1016\/j.brachy.2026.08.004_bib0007","doi-asserted-by":"crossref","first-page":"441","DOI":"10.5114\/jcb.2020.100377","article-title":"Excess dose-related parameters (Vex, Rex, and iRex): novel predictors and late toxicity correlations in cervical cancer image-guided adaptive brachytherapy","volume":"12","author":"Prasartseree","year":"2020","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.brachy.2026.08.004_bib0008","first-page":"48","article-title":"The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies","volume":"9","author":"P\u00f6tter","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.brachy.2026.08.004_bib0009","unstructured":"Anon. Common terminology criteria for adverse events (CTCAE) | Protocol Development | CTEP."},{"key":"10.1016\/j.brachy.2026.08.004_bib0010","series-title":"*Stata statistical software: release 17*","year":"2021"},{"key":"10.1016\/j.brachy.2026.08.004_bib0011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.conctc.2017.04.008","article-title":"Design of phase II non-inferiority trials","volume":"7","author":"Jung","year":"2017","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.brachy.2026.08.004_bib0012","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ijrobp.2004.04.053","article-title":"Concurrent chemotherapy and hypofractionated twice-daily radiotherapy in cervical cancer patients with stage IIIB disease and bilateral parametrial involvement: a phase I-II study","volume":"60","author":"Viegas","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2026.08.004_bib0013","first-page":"127","article-title":"Hypofractionated radiotherapy in carcinoma cervix IIIB: Tata Memorial Hospital experience","volume":"39","author":"Muckaden","year":"2002","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.brachy.2026.08.004_bib0014","unstructured":"Trade and policy strategy office, Ministry of Commerce. Consumer Price Index (CPI)."},{"key":"10.1016\/j.brachy.2026.08.004_bib0015","unstructured":"Anon. Standard cost list for health technology assessment."},{"key":"10.1016\/j.brachy.2026.08.004_bib0016","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40273-020-00914-6","article-title":"Calculating and interpreting ICERs and net benefit","volume":"38","author":"Paulden","year":"2020","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.brachy.2026.08.004_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1552346","article-title":"A comparative analysis of hypofractionated versus conventional radiotherapy for cervical cancer in a resource-limited setting: a prospective study","volume":"15","author":"Mallum","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.brachy.2026.08.004_bib0018","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.ijrobp.2024.07.014","article-title":"Moderated hypofractionated online adaptive radiotherapy in locally advanced cervical cancer: a prospective 1 clinical trial","volume":"120","author":"Zeng","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2026.08.004_bib0019","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00432-023-05563-8","article-title":"Hypofractionated versus standard chemoradiotherapy in the definitive treatment of uterine cervix cancer: interim results of a randomized controlled clinical trial","volume":"150","author":"Maddah Safaei","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.brachy.2026.08.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.07.500","article-title":"A pilot study of moderately hypo-fractionated whole pelvic radiotherapy with concurrent chemotherapy and image-guided high dose rate brachytherapy for locally advanced cervical carcinoma","volume":"114","author":"Gandhi","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2026.08.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2022.110243","article-title":"A meta-analysis of MRI-based radiomic features for predicting lymph node metastasis in patients with cervical cancer","volume":"151","author":"Li","year":"2022","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.brachy.2026.08.004_bib0022","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.3390\/cancers15205105","article-title":"An update on the role of MRI in treatment stratification of patients with cervical cancer","volume":"15","author":"Shakur","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.brachy.2026.08.004_bib0023","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.rpor.2018.05.002","article-title":"Problems and solutions in IGRT for cervical cancer","volume":"23","author":"R\u00edos","year":"2018","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.brachy.2026.08.004_bib0024","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tipsro.2019.10.007","article-title":"RTT-led IGRT for cervix cancer; training, implementation and validation","volume":"12","author":"Alexander","year":"2019","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"10.1016\/j.brachy.2026.08.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70269","article-title":"Weekly image guidance in patients with cervical cancer treated with intensity-modulated radiation therapy: results of a large cohort study","volume":"13","author":"Zeng","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.brachy.2026.08.004_bib0026","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.ijrobp.2025.03.051","article-title":"A prospective single-arm study of daily online adaptive radiation therapy for cervical cancer with reduced planning target volume margin: acute toxicity and dosimetric outcomes","volume":"122","author":"Wang","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2026.08.004_bib0027","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.radonc.2016.06.006","article-title":"Dose\u2013volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: results from the prospective multicenter EMBRACE study","volume":"120","author":"Mazeron","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2026.08.004_bib0028","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.radonc.2016.05.014","article-title":"Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer","volume":"120","author":"Tanderup","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2026.08.004_bib0029","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.brachy.2019.02.007","article-title":"Radiobiological dose calculation parameters for cervix cancer brachytherapy: a systematic review","volume":"18","author":"Chow","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2026.08.004_bib0030","doi-asserted-by":"crossref","first-page":"S837","DOI":"10.1016\/S0167-8140(25)01194-6","article-title":"2638 EMBRACE II - a multicenter prospective interventional cohort study on IGRT-IMRT+cisplatin+MR-IGABT in locally advanced cervix cancer: overall results","volume":"206","author":"P\u00f6tter","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2026.08.004_bib0031","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2025.05.068","article-title":"Impact of patient selection on real-world outcomes by using the EMBRACE-II treatment protocol in locally advanced cervical cancer","volume":"123","author":"Lindegaard","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2026.08.004_bib0032","article-title":"Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: final analysis results of the phase 3, randomized, double-blind ENGOT-cx11\/GOG-3047\/KEYNOTE-A18 study","author":"Xiang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2026.08.004_bib0033","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.brachy.2026.08.004_bib0034","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.brachy.2026.08.004_bib0035","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(24)01438-7","article-title":"Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial","volume":"404","author":"McCormack","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.brachy.2026.08.004_bib0036","doi-asserted-by":"crossref","first-page":"S1110","DOI":"10.1016\/S0167-8140(24)03072-X","article-title":"2976: CT- VS MRI-based bone marrow dose in CCRT for cervix cancer: a pooled data from 2 prospective trials","volume":"194","author":"Chanwichu","year":"2024","journal-title":"Radiother Oncol"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472126003065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472126003065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:34:09Z","timestamp":1792841649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472126003065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1538472126003065"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2026.08.004","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated 44 Gy in 20 fractions versus conventional chemoradiation in cervical cancer: 2-year results of the randomized HYPOCx-iRex trial with an exploratory pooled analysis of a single-institute EMBRACE-II cohort","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2026.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Brachytherapy Society.","name":"copyright","label":"Copyright"}]}}